Singulex withdraws $70 million IPO

Singulex, which provides diagnostic testing for cardiovascular disease in a non-acute setting, withdrew its plans for an initial public offering on Friday citing poor market conditions. Singulex had postponed its planned $70 million offering in November. The Alameda, CA-based company was founded in 1997 and booked $38 million in sales for the 12 months ended 6/30/2012. UBS Investment Bank and Piper Jaffray were set to be the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.